An Interventional, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy and Safety of Infliximab in Subject With Moderate-to-Severe Refractory Intestinal Behcet's Disease

Trial Profile

An Interventional, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy and Safety of Infliximab in Subject With Moderate-to-Severe Refractory Intestinal Behcet's Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Aug 2017

At a glance

  • Drugs Infliximab (Primary)
  • Indications Behcet's syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms BEGIN
  • Sponsors Janssen Biotech
  • Most Recent Events

    • 08 Aug 2017 Planned End Date changed from 9 Apr 2018 to 31 Jan 2019.
    • 11 Jul 2017 Planned End Date changed from 31 Dec 2017 to 9 Apr 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top